OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
EL8$0.2757

Elevate Uranium Ltd

UraniumVerified

Elevate Uranium Ltd maintains a strong liquidity position, with cash and equivalents totaling AUD 15.17 million, representing 63.4% of total assets. The company’s liquidity ratio of 17.74 indicates a robust ability to cover short-term liabilities, and its debt-to-equity ratio of 0.02 suggests minimal leverage. The price-to-book ratio of 5.17 implies that the market values the company at a premium to its book value, which may reflect expectations of future asset value appreciation or exploration success. The company is currently unprofitable, with a net loss of AUD 12.32 million and a return on equity of -51.6%, significantly below the industry median for uranium exploration firms. Operating income of -AUD 12.28 million and a negative gross profit of -AUD 655,630 highlight the capital-intensive nature of uranium exploration and the absence of revenue-generating operations to date. Elevate Uranium’s geographic exposure is concentrated in Namibia and Australia, with its flagship projects in the Erongo uranium province and the Flinders Ranges. The Koppies Uranium Project and Marenica Uranium Project in Namibia cover 321 square kilometers, while the Napperby Uranium Project in Australia is located near existing uranium mines, suggesting potential for resource synergies. However, the company does not disclose segment-specific revenue, and all operations are currently in the exploration phase. The company’s growth trajectory is speculative, with no revenue growth reported in the latest financial period. The outlook for the current fiscal year does not include material revenue increases, and no forward-looking guidance is provided. The absence of production and reliance on exploration spending, which totaled AUD 85,130 in the latest period, suggests that profitability is contingent on successful resource delineation and project advancement. Risk factors include the high volatility of uranium prices, regulatory and permitting delays in both Namibia and Australia, and the capital-intensive nature of exploration. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company’s equity valuation is sensitive to exploration outcomes and uranium market dynamics. Recent events include the continuation of exploration activities in Namibia and Australia, with no material changes in ownership or financing disclosed in the latest filings. The company has not issued new shares or raised capital in the most recent period, and no significant operational or strategic developments were reported.

30-day price · EL8+0.01 (+1.9%)
Low$0.25High$0.36Close$0.27As of12 May, 00:00 UTC
Profile
CompanyElevate Uranium Ltd
TickerEL8.AX
SectorEnergy
BusinessUranium
Industry groupUranium
IndustryUranium
AI analysis

Business. Elevate Uranium Ltd is an Australia-based uranium exploration and development company focused on the exploration and evaluation of mineral tenements in Namibia and Australia, including the Koppies Uranium Project, Marenica Uranium Project, and Napperby Uranium Project.

Classification. Elevate Uranium Ltd is classified under the Energy sector, Uranium business sector, and Uranium industry with a confidence level of 0.92.

Elevate Uranium Ltd maintains a strong liquidity position, with cash and equivalents totaling AUD 15.17 million, representing 63.4% of total assets. The company’s liquidity ratio of 17.74 indicates a robust ability to cover short-term liabilities, and its debt-to-equity ratio of 0.02 suggests minimal leverage. The price-to-book ratio of 5.17 implies that the market values the company at a premium to its book value, which may reflect expectations of future asset value appreciation or exploration success. The company is currently unprofitable, with a net loss of AUD 12.32 million and a return on equity of -51.6%, significantly below the industry median for uranium exploration firms. Operating income of -AUD 12.28 million and a negative gross profit of -AUD 655,630 highlight the capital-intensive nature of uranium exploration and the absence of revenue-generating operations to date. Elevate Uranium’s geographic exposure is concentrated in Namibia and Australia, with its flagship projects in the Erongo uranium province and the Flinders Ranges. The Koppies Uranium Project and Marenica Uranium Project in Namibia cover 321 square kilometers, while the Napperby Uranium Project in Australia is located near existing uranium mines, suggesting potential for resource synergies. However, the company does not disclose segment-specific revenue, and all operations are currently in the exploration phase. The company’s growth trajectory is speculative, with no revenue growth reported in the latest financial period. The outlook for the current fiscal year does not include material revenue increases, and no forward-looking guidance is provided. The absence of production and reliance on exploration spending, which totaled AUD 85,130 in the latest period, suggests that profitability is contingent on successful resource delineation and project advancement. Risk factors include the high volatility of uranium prices, regulatory and permitting delays in both Namibia and Australia, and the capital-intensive nature of exploration. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company’s equity valuation is sensitive to exploration outcomes and uranium market dynamics. Recent events include the continuation of exploration activities in Namibia and Australia, with no material changes in ownership or financing disclosed in the latest filings. The company has not issued new shares or raised capital in the most recent period, and no significant operational or strategic developments were reported.
Key takeaways
  • Elevate Uranium Ltd is a uranium exploration company with no current production and a strong liquidity position.
  • The company is unprofitable, with a net loss of AUD 12.32 million and a negative return on equity of -51.6%.
  • Geographic exposure is concentrated in Namibia and Australia, with flagship projects in the Erongo and Flinders Ranges.
  • Growth is speculative and contingent on successful exploration and uranium price trends.
  • Risk factors include regulatory delays, exploration costs, and market volatility, but liquidity and dilution risks are currently low.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyAUD
Revenue$768.5k
Gross profit-$655.6k
Operating income-$12.3M
Net income-$12.3M
R&D
SG&A
D&A
SBC
Operating cash flow-$11.6M
CapEx-$85.1k
Free cash flow-$12.2M
Total assets$25.5M
Total liabilities$1.6M
Total equity$23.9M
Cash & equivalents$15.2M
Long-term debt$432.4k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$0.27
Market cap$123.5M
Enterprise value$108.7M
P/E
Reported non-GAAP P/E
EV/Revenue141.5
EV/Op income
EV/OCF
P/B5.2
P/Tangible book5.2
Tangible book$23.9M
Net cash$14.7M
Current ratio17.7
Debt/Equity0.0
ROA-48.4%
ROE-51.6%
Cash conversion94.0%
CapEx/Revenue-11.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Uranium · cohort 1 companies
MetricEL8Activity
Op margin-1597.9%11.2% medp25 11.2% · p75 11.2%bottom quartile
Net margin-1603.7%17.3% medp25 17.3% · p75 17.3%bottom quartile
Gross margin-85.3%26.2% medp25 26.2% · p75 26.2%bottom quartile
R&D / revenue3.8% medp25 3.8% · p75 3.8%
CapEx / revenue-11.1%4.4% medp25 4.4% · p75 4.4%bottom quartile
Debt / equity2.0%0.1% medp25 0.0% · p75 1.8%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 11:13 UTC#a4b968d3
Market quoteclose AUD 0.27 · shares 0.47B diluted
no public URL
2026-05-10 11:13 UTC#3f3bea22
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 11:16 UTCJob: b757f7cd